Alexa Wonnacott
Overview
Explore the profile of Alexa Wonnacott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roddick A, Wonnacott A, Webb D, Watt A, Watson M, Staplin N, et al.
BMC Nephrol
. 2023 Oct;
24(1):310.
PMID: 37880609
Large placebo-controlled trials have demonstrated kidney and cardiovascular clinical benefits of SGLT-2 inhibitors. Data from the EMPA-KIDNEY and DELIVER trials and associated meta-analyses triggered an update to the UK Kidney...
2.
Wonnacott A
Clin Med (Lond)
. 2023 May;
23(3):254-258.
PMID: 37236791
Chronic kidney disease (CKD) represents an enormous healthcare burden, the management of which has been stagnant for the last couple of decades, with blockade of the renin-angiotensin-aldosterone system (RAAS) the...
3.
Wonnacott A, Denby L, Coward R, Fraser D, Bowen T
Adv Drug Deliv Rev
. 2021 Nov;
182:114045.
PMID: 34767865
The global prevalence of diabetes mellitus was estimated to be 463 million people in 2019 and is predicted to rise to 700 million by 2045. The associated financial and societal...
4.
Staplin N, Roddick A, Emberson J, Reith C, Riding A, Wonnacott A, et al.
EClinicalMedicine
. 2021 Nov;
41:101163.
PMID: 34765951
Background: The net absolute effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors across different patient groups have not been quantified. Methods: We performed a meta-analysis of published large (>500 participants/arm) placebo-controlled SGLT-2...
5.
Newbury L, Wonnacott A, Simpson K, Bowen T, Fraser D
Methods Mol Biol
. 2019 Nov;
2067:277-285.
PMID: 31701457
Urinary microRNAs show promise as noninvasive biomarkers in renal disease. Here, we describe a detailed protocol for the column-based extraction and quantification of miRNAs by reverse-transcription quantitative polymerase chain reaction...
6.
Beltrami C, Simpson K, Jesky M, Wonnacott A, Carrington C, Holmans P, et al.
Am J Pathol
. 2018 Jul;
188(9):1982-1992.
PMID: 29981742
Effective diabetic kidney disease (DKD) biomarkers remain elusive, and urinary miRNAs represent a potential source of novel noninvasive disease sentinels. We profiled 754 miRNAs in pooled urine samples from DKD...
7.
Wonnacott A, Bowen T, Fraser D
Curr Opin Nephrol Hypertens
. 2017 Aug;
26(6):460-466.
PMID: 28806192
Purpose Of Review: This review summarizes recent data supporting the concept that urinary microRNAs are a useful new class of biomarker. They may improve capacity to stratify patients with chronic...
8.
Simpson K, Wonnacott A, Fraser D, Bowen T
Curr Diab Rep
. 2016 Mar;
16(3):35.
PMID: 26973290
Recent estimates suggest that 1 in 12 of the global population suffers from diabetes mellitus. Approximately 40 % of those affected will go on to develop diabetes-related chronic kidney disease...
9.
Johnson F, Phillips D, Talabani B, Wonnacott A, Meran S, Phillips A
Nephrology (Carlton)
. 2015 Oct;
21(6):506-11.
PMID: 26452246
Background: Little data exist on outcome of acute kidney injury (AKI) in diabetes. We describe short-term recovery of renal function, patient mortality and progressive renal dysfunction following AKI in diabetic...
10.
Meran S, Wonnacott A, Amphlett B, Phillips A
Clin Kidney J
. 2015 Apr;
7(2):144-50.
PMID: 25852863
Introduction: Acute kidney injury (AKI) is a common clinical problem associated with adverse outcomes. This study identifies the incidence of AKI in two UK district general hospitals' without on-site renal...